Case Study: Implementing Real-Time Stability Testing for Oral Solid Dosage Forms
Real-time stability testing is a regulatory requirement and quality assurance cornerstone in the pharmaceutical industry. This expert case study explores the end-to-end implementation of real-time stability testing for oral solid dosage forms (tablets and capsules), highlighting ICH compliance, protocol design, and actionable lessons for pharmaceutical professionals.
Background and Product Overview
This case involves a fixed-dose combination (FDC) of two antihypertensive agents in film-coated tablet form. The product was intended for global submission, including regions in Climatic Zones II, III, and IVb. The project aimed to establish a shelf life of 24 months using real-time data compliant with ICH Q1A(R2).
Formulation Details:
- Tablet form with core and film coat
- Moisture-sensitive API in one component
- PVC-Alu blister as the final container
1. Protocol Design and Objective
The protocol was designed to demonstrate long-term stability under recommended storage conditions. Objectives included shelf-life determination, regulatory support for NDAs, and formulation validation.
Key Protocol Elements:
- Storage Conditions: 25°C ± 2°C / 60% RH ± 5% RH (Zone II); additional studies at 30°C/75% RH for Zone IVb
- Duration: 0, 3, 6, 9, 12, 18, 24 months
- Sample Type: Three production-scale batches
- Testing Parameters: Assay, dissolution, related substances, water content,
2. Selection of Representative Batches
Three commercial-scale batches were selected, each manufactured using validated processes and packaged in final market-intended packaging. One batch incorporated the maximum theoretical impurity profile to serve as the worst-case scenario.
Batch Handling Notes:
- Batch IDs: FDC1001, FDC1002, FDC1003
- Blister-packed and sealed within 24 hours post-manufacture
- Samples split between primary and backup stability chambers
3. Stability Chamber Setup and Qualification
The real-time study was conducted in ICH-qualified chambers maintained at 25°C/60% RH and 30°C/75% RH. All chambers underwent IQ/OQ/PQ and were mapped for uniformity before sample placement.
Monitoring Parameters:
- Temperature and RH probes calibrated quarterly
- Automated deviation alerts and backup power system
4. Analytical Method Validation
All test parameters were evaluated using stability-indicating methods validated according to ICH Q2(R1).
Key Analytical Methods:
- Assay and impurities: HPLC with dual wavelength detection
- Dissolution: USP Apparatus 2, 900 mL media
- Water Content: Karl Fischer titration
- Physical tests: Hardness tester, friability drum
5. Stability Data Summary
Results from 0 to 24 months showed consistent performance across all three batches. No significant degradation was observed, and all critical parameters remained within specification.
Tabulated Data Snapshot:
| Time Point | Assay (% label) | Total Impurities (%) | Dissolution (%) | Water Content (%) |
|---|---|---|---|---|
| 0 Months | 99.2 | 0.15 | 98.5 | 1.8 |
| 12 Months | 98.9 | 0.21 | 98.3 | 1.9 |
| 24 Months | 98.4 | 0.27 | 97.8 | 2.0 |
6. Observations and Key Learnings
Despite the presence of a moisture-sensitive API, the film coating and PVC-Alu packaging provided excellent protection. No unexpected impurities formed, and the dissolution profile remained consistent across time points.
Lessons Learned:
- Packaging selection critically impacts moisture control
- Worst-case batch strategy is valuable in predicting long-term behavior
- Dual-chamber redundancy improves data reliability and risk mitigation
7. Regulatory Submission and Approval
The real-time stability data formed part of Module 3.2.P.8.3 of the CTD submitted to regulatory authorities. No data gaps or deficiencies were noted during the review, and a 24-month shelf life was granted without the need for additional justification.
Supporting SOPs, protocols, and validation templates are available at Pharma SOP. For more such real-time case explorations, visit Stability Studies.
Conclusion
This case study demonstrates the successful implementation of a real-time stability program for oral solid dosage forms. With careful batch selection, validated methods, and robust chamber controls, pharmaceutical professionals can generate high-quality data that support regulatory filings and ensure long-term product integrity.